Telix Enters Collaboration with DKFZ Researchers to Develop Image-Guided Surgery

Telix Enters Collaboration with DKFZ Researchers to Develop Image-Guided Surgery
Telix Pharmaceuticals has established a collaboration agreement with a team of researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, or DKFZ) to develop an innovative image-guided surgery for men with prostate cancer. Investigators from the DKFZ and Heidelberg University Clinic have been working on the development of a next-generation radiotracer — a radioactive compound that may be administered to patients to "light up" tumors in positron emission tomography (PET) scans. It is based on Telix's TLX591-CDx (68Ga-PSMA-11), marketed in the U.S. under the brand name Illumet. Besides emitting radiation required for PET, the new compound also contains a fluorescing agent (fluorophore) that is visible through optical imaging. For this reason, the compound may be simultaneously used as a standard radiotracer agent to image prostate cancer through PET, and as a fluorescent agent to guide surgeons during prostate surgery. Image-guided fluorescence imaging is a standard feature of many modern systems. It is based on the use of automated surgical robots that are widely used across the globe during urologic surgeries. One example is the Firefly imaging system, part of the da Vinci surgical robotics system by Intuitive Surgical. "The astonishing research of our colleagues at DKFZ and Heidelberg has tremendous potential in improving the quality and efficiency of using image-guided techniques for robotic surgery," Christian Behrenbruch, CEO of Telix, said in a press release. "To date, Telix has focused on using PSMA imaging in the post-prostatectomy [prostate removal] biochemical recurrence setting. This collaboration will explore how the combination of PET and image-guided surgery can be used to improve outcomes during prostatectomy, further e
Subscribe or to access all post and page content.